Drug profile · INN
tesamorelin acetate
EGRIFTA
tesamorelin acetate (EGRIFTA) is a growth hormone-releasing hormone receptor agonist. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — tesamorelin acetate
- US status
- approved
- Class
- —
- Route
- SUBCUTANEOUS
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
tesamorelin acetate (EGRIFTA) is a growth hormone-releasing hormone receptor agonist. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Growth hormone-releasing hormone receptor agonist
Primary target: Growth hormone-releasing hormone receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is tesamorelin acetate?
tesamorelin acetate (EGRIFTA) is a growth hormone-releasing hormone receptor agonist. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for tesamorelin acetate?
EGRIFTA is a marketed brand name for tesamorelin acetate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of tesamorelin acetate?
tesamorelin acetate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.